We mined Novartis’ acquisitions, investments, and partnerships to discern the company's strategic priorities.
Novartis’ $196B valuation puts it among the top 10 most valuable pharmaceutical companies in the world.
Over the last several years, Novartis has acquired, partnered with, and invested in companies that support its mission to leverage artificial intelligence (AI) and other technology to improve its processes and create new products.
One core theme across Novartis’ investment activity is using patient data to improve drug development and commercialization. For example, the pharma giant has backed Koneksa, which is applying AI to clinical trial data to develop new digital biomarkers. Novartis also invested in Alto Neuroscience’s brain biomarker technology, which aims to enhance the way patients are matched to psychiatric drugs.
Using CB Insights data, we uncovered the 5 most important strategic priorities highlighted by Novartis’ recent acquisitions, investments, and partnerships. We then categorized companies by their business relationships with Novartis across these priorities.
- Clinical trials
- Diagnostics
- Digital therapeutics
- Patient access
- Real-world data
These designations are not exhaustive of Novartis’ investment and partnership activity in the analyzed period.
